Tesi and Debiopharm in $10m series-B for BC Platforms
Finnish VC investor Tesi and Swiss biopharmaceutical group Debiopharm have invested in a $10m series-B funding round for Basel-based genomic data management company BC Platforms.
More on DACH
CVC to buy sports nutrition specialist The Quality Group
GP to acquire majority stake via Fund VIII; German group’s founders to reinvest in the deal
DBAG to target EUR 1.3bn-EUR 1.5bn for new buyout fund next year
German GP’s new vehicle will be slightly larger than its predecessor, which is set to complete deployment in two years
EMZ in final stretch of EUR 1.2bn EMZ 10 fundraise
EMZ 10 held a first close in excess of EUR 800m earlier in May and continues to seek new LPs
Nord Holding hires Ufenau’s Kukwa
Christian Kukwa spent two years with Ufenau and will focus on business services in his new role
Latest News
Verdane scores 5x MOIC in partial exit of Inriver to THL
Majority investment from THL Partners sees Verdane retain a minority stake in the Swedish company
CVC to buy sports nutrition specialist The Quality Group
GP to acquire majority stake via Fund VIII; German group’s founders to reinvest in the deal
DBAG to target EUR 1.3bn-EUR 1.5bn for new buyout fund next year
German GP’s new vehicle will be slightly larger than its predecessor, which is set to complete deployment in two years
Alcedo heads for June final close for Fund V
Italian GP has received EUR 230m in commitments to date for Fund V against a EUR 250m hard-cap